Teva Pharmaceutical Industries Ltd

Teva's CEO has flagged uncertainty around a proposed US tariff plan for generic-drug imports set to take effect in two years. The company raised its 2026 revenue outlook to $16.5–16.85 billion, driven by strong growth in its three flagship branded drugs-Austedo, Ajovy, and Uzedy-which together generated over $1 billion in quarterly revenue and grew 43% year-over-year. Despite near-term earnings pressure from the $726 million Emalex Biosciences acquisition, investors focused on Teva's pivot to branded medicines, pushing shares up sharply.